NasdaqGS:UTHRBiotechs
Will Insider Stock Sales Amid EXPAND Xenotransplantation Progress Change United Therapeutics' (UTHR) Narrative?
In December 2025, several United Therapeutics insiders, including officer Paul A. Mahon and directors Jan Malcolm and Christopher Patusky, disclosed past sales of company stock totaling more than US$5.33 million, as required under federal securities laws.
These insider transactions came as analysts highlighted encouraging clinical progress, including the first clinical xenotransplantation in the EXPAND study, alongside a solid operational backdrop for United Therapeutics.
We’ll explore how...